Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors.

29 Jul 2021

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

Collaborative teams that include Southwest Research Institute staff received two of six recently awarded San Antonio Medical Foundation (SAMF) bioscience grants. SwRI, in collaboration with UT Health San Antonio and University Health System, received a nearly $200,000 grant to develop machine learning algorithms for cancer detection.

31 Mar 2021

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

An interesting new preprint published on the medRxiv server describes an immunosuppressed patient with coronavirus disease 2019 (COVID-19) who continued to shed the virus for an astounding 154 days. During this period, the virus underwent numerous mutations.

19 Jan 2021

MDC researchers develop a potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

11 Jan 2021

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial.

6 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020

Combining two immunotherapies into a single treatment found to be more effective

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer. But immunotherapies don't work in all patients, and researchers have been searching for ways to increase their effectiveness.

23 Jul 2020

Study shows potential new approach to treating two common subtypes of lymphoma

A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein.

8 Jan 2020

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

People with follicular lymphoma, a slow-growing lymphatic-system cancer, who have been treated and are in remission for at least two years, may no longer have what has been considered an incurable disease based on highly sensitive testing.

9 Dec 2019

$Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission$

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

8 Dec 2019

Cancer patients share survivorship story, celebrate strength and self-care

To survive in his struggle against an aggressive form of prostate cancer, Bin McLaurin didn't only have to overcome the disease attacking his body. He said he also had to toss out his long-held image of masculinity.

16 Jun 2019

HCA Healthcare UK introduces ground-breaking new blood cancer treatment

HCA Healthcare UK has announced the launch of CAR T-cell therapy - a ground-breaking new blood cancer treatment which will be available to eligible patients with Diffuse Large B-Cell Lymphoma and Acute Lymphoblastic Leukaemia.

3 Apr 2019

T-cells play key role in how the body fights follicular lymphoma

Healthy white blood cells, called "T-cells," play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, M.D., Ph.D., that was published in Cell Reports.

20 Feb 2019

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

3 Dec 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany.

10 Oct 2018

Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

MDC researchers develop a potent weapon against lymphomas

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Combining two immunotherapies into a single treatment found to be more effective

Study shows potential new approach to treating two common subtypes of lymphoma

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Cancer patients share survivorship story, celebrate strength and self-care

HCA Healthcare UK introduces ground-breaking new blood cancer treatment

T-cells play key role in how the body fights follicular lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Everything you should know about lymphoma eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

Everything you should know about lymphoma eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in